IVERIC bio, Inc. (ISEE)
| Market Cap | 1.75B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -107.82M |
| Shares Out | 93.41M |
| EPS (ttm) | -1.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,035,308 |
| Open | 18.30 |
| Previous Close | 17.91 |
| Day's Range | 16.32 - 18.85 |
| 52-Week Range | 4.96 - 18.85 |
| Beta | 1.32 |
| Analysts | Strong Buy |
| Price Target | 22.00 (+30.6%) |
| Est. Earnings Date | Nov 1, 2021 |
About ISEE
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for IVERIC bio stock is "Strong Buy." The 12-month stock price forecast is 22.00, which is an increase of 30.56% from the latest price.
News
Iveric Bio Announces Pricing of Upsized Public Offering of Common Stock
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced the pricing of an upsized underwritten public offering of 9,000,000 shares of its common stock at $16.75 per share to the public.
Iveric Bio Announces Proposed Offering of Common Stock
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it is commencing an underwritten public offering of $125.0 million of shares of its common stock.
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Iveric Bio granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to eight newly-hired, non-executive employees.
Iveric Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK--(BUSINESS WIRE)--Iveric announced that Pravin Dugel, M.D., President, will present an overview of the Company at the 2021 H.C. Wainwright Global Investment Conference.
Here's Why Iveric Bio Stock Is Rocketing Higher Today
Mixed results from Apellis Pharmaceuticals are good news for Iveric Bio's geographic atrophy program.
ISEE Stock: Why Rival Eye Drug Developer's Disappointment Is a Boon to IVERIC bio
IVERIC bio (ISEE) stock is rocketing higher on Friday and there's a couple of catalysts behind the shares' positive movement today. The post ISEE Stock: Why Rival Eye Drug Developer's Disappointment Is ...
Why IVERIC Bio Shares Are Soaring Today
IVERIC Bio Inc (NASDAQ: ISEE) is trading significantly higher Friday after Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported results from its Phase 3 DERBY and OAKS studies in geographic atrophy. Apel...
Why Are Iveric Bio Shares Surging In Premarket Friday?
Iveric Bio Inc (NASDAQ:ISEE) stock is trading almost 50% higher as the investors are cheering Stifel's initiated coverage on Iveric Bio with a Buy rating and a price target of $22.00. Analyst Annabel Sa...
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Iveric Bio granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to three newly-hired, non-executive employees.
New Strong Sell Stocks for August 18th
CYTK, GEVO, ISEE, MCFE, and NOMD have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2021.
Implied Volatility Surging for IVERIC bio (ISEE) Stock Options
Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.
Iveric Bio to Present at the H.C. Wainwright Ophthalmology Virtual Conference
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that the Company will participate in the H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17 2021.
Iveric Bio to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that Pravin U. Dugel, M.D., President, will participate in a panel at the Wedbush Conference on Wed., Aug. 11 at 8:00 a.m. ET.
Iveric Bio Reports Second Quarter 2021 Operational Highlights and Financial Results
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the quarter ended June 30, 2021 and provided a general business update.
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Iveric Bio granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to five newly hired employees.
Iveric Bio to Report Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it will report its second quarter 2021 financial and operating results on Wednesday, August 4, 2021.
Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of Schedule
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced the early completion of patient enrollment of GATHER2, the Company's 2nd pivotal clinical trial of Zimura® (avacincaptad pegol).
Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
Penny Stocks & Small Caps Jump As Biotech Industry Names Kick Into High Gear The post Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech appeared first on Penny Stocks to Buy, Picks, News a...
Iveric Bio Appoints Christopher Simms as Chief Commercial Officer
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced today the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2, 2021.
IVERIC bio (ISEE) Enters Overbought Territory
IVERIC bio (ISEE) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
Iveric Bio Raises $100M Via Equity To Fund Zimura Development In Geographic Atrophy
Iveric bio Inc (NASDAQ: ISEE) priced its underwritten public offering of 11.6 million shares at $8.60 per share, representing a discount of 4.6% from the last close price of $9.01 on Monday. Underwriter...
IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced the pricing of an underwritten public offering of 11,650,000 shares of its common stock.
IVERIC bio, Inc. Announces Proposed Offering of Common Stock
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it is commencing an underwritten public offering of shares of its common stock.
Do Options Traders Know Something About IVERIC bio (ISEE) Stock We Don't?
Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.
Iveric Bio Stock Jumps Higher On SPA Agreement From FDA For Zimura Study In Geographic Atrophy
Iveric Bio Inc (NASDAQ: ISEE) has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the overall design of the GATHER2 trial of Zimura (avacincaptad pegol) for geograp...